drugset / Trial / NCT05939648
A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021)
Phase 2
Unknown
450 enrolled
AIM Vaccine Co., Ltd.
Ningbo Rongan Biological Pharmaceutical Co., Ltd. · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
This trial is a phase II clinical trial of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021). The trial was randomized, blinded, placebo controlled. To evaluate the safety and immunogenicity of the study vaccine in participants aged 18 years and older who have received SARS-CoV-2 Vaccine.
Timeline
- Start
- 2023-10-09
- Primary completion
- 2023-11-30
- Completion
- 2024-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SARS-CoV-2 Bivalent mRNA Vaccine | Messenger RNA (mRNA) | 100 ug | Intramuscular |